Is Macrobid (Nitrofurantoin) safe during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Macrobid (Nitrofurantoin) is safe to use during pregnancy.

Evidence Summary

  • The Infectious Diseases Society of America guidelines support the use of nitrofurantoin in pregnant women with asymptomatic bacteriuria, as it decreases the risk of pyelonephritis and low-birth-weight infants 1.
  • A prospective, controlled trial randomized bacteriuric women to receive a 1-week course of therapy with nitrofurantoin, demonstrating its effectiveness in preventing adverse outcomes 1.
  • A Cochrane review found that 7 days of nitrofurantoin therapy was more effective than a single dose in preventing lower birth weight, although no differences in pyelonephritis or preterm delivery were observed between the 2 study arms 1.
  • Nitrofurantoin is preferred due to its safety in pregnant women, although it may be less effective as short-course therapy for treatment of acute cystitis in women 1.

Key Points

  • Nitrofurantoin dosage: typically a 4- to 7-day course of therapy, although the optimal duration may be antimicrobial-specific 1.
  • Safety: nitrofurantoin is considered safe for use in pregnant women, with a low risk of adverse effects 1.
  • Benefits: treatment of asymptomatic bacteriuria with nitrofurantoin decreases the risk of pyelonephritis, low-birth-weight infants, and preterm delivery 1.

From the Research

Safety of Macrobid (Nitrofurantoin) during Pregnancy

  • The safety of Macrobid (Nitrofurantoin) during pregnancy has been evaluated in several studies, with varying results 2, 3, 4, 5, 6.
  • A retrospective analysis of 91 pregnancies found no evidence that nitrofurantoin macrocrystals were toxic to the fetus or unsafe for treatment of maternal urinary tract infection during pregnancy 2.
  • A systematic review and meta-analysis of 8 studies found that exposure to nitrofurantoin during early pregnancy was not associated with an increased risk of major malformations in cohort studies, but a slight increase in risk was found in case-control studies 3.
  • Another study found that postcoital prophylaxis with nitrofurantoin macrocrystals was effective in preventing recurrent urinary tract infections during pregnancy 4.
  • A review of the risks of antibacterial agents in pregnancy found that nitrofurantoin is a valid option in pregnancy, except in the latter stages, due to the risk of hemolytic anemia in the newborn 5, 6.
  • A case report described a newborn who developed hemolytic anemia after maternal treatment with nitrofurantoin at the end of pregnancy, highlighting the potential risks of using this medication during this time 6.

Potential Risks and Considerations

  • The use of nitrofurantoin during pregnancy may be associated with an increased risk of certain malformations, such as hypoplastic left heart syndrome 3.
  • The medication may also pose a risk of hemolytic anemia in the newborn, particularly if used during the latter stages of pregnancy 5, 6.
  • As with any medication, the potential benefits and risks of using nitrofurantoin during pregnancy must be carefully considered, and alternative treatments may be recommended in some cases 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2015

Research

Effective prophylaxis for recurrent urinary tract infections during pregnancy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Research

[Risks of antibacterial agents in pregnancy].

Le infezioni in medicina, 2002

Research

[Hemolytic anemia in a newborn after maternal treatment with nitrofurantoin at the end of pregnancy].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.